BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 36433941)

  • 21. Combination of hepatocyte specific delivery and transformation dependent expression of shRNA inducing transcriptional gene silencing of c-Myc promoter in hepatocellular carcinoma cells.
    Zakaria MK; Khan I; Mani P; Chattopadhyay P; Sarkar DP; Sinha S
    BMC Cancer; 2014 Aug; 14():582. PubMed ID: 25108398
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Myelocytomatosis-Protein Arginine N-Methyltransferase 5 Axis Defines the Tumorigenesis and Immune Response in Hepatocellular Carcinoma.
    Luo Y; Gao Y; Liu W; Yang Y; Jiang J; Wang Y; Tang W; Yang S; Sun L; Cai J; Guo X; Takahashi S; Krausz KW; Qu A; Chen L; Xie C; Gonzalez FJ
    Hepatology; 2021 Oct; 74(4):1932-1951. PubMed ID: 33896016
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Indian Hedgehog links obesity to development of hepatocellular carcinoma.
    Chong YC; Lim TE; Fu Y; Shin EM; Tergaonkar V; Han W
    Oncogene; 2019 Mar; 38(12):2206-2222. PubMed ID: 30470823
    [TBL] [Abstract][Full Text] [Related]  

  • 24. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
    Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
    Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.
    Song CQ; Li Y; Mou H; Moore J; Park A; Pomyen Y; Hough S; Kennedy Z; Fischer A; Yin H; Anderson DG; Conte D; Zender L; Wang XW; Thorgeirsson S; Weng Z; Xue W
    Gastroenterology; 2017 Apr; 152(5):1161-1173.e1. PubMed ID: 27956228
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PTTG1 is involved in TNF-α-related hepatocellular carcinoma via the induction of c-myc.
    Lin X; Yang Y; Guo Y; Liu H; Jiang J; Zheng F; Wu B
    Cancer Med; 2019 Sep; 8(12):5702-5715. PubMed ID: 31385458
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Notch activity characterizes a common hepatocellular carcinoma subtype with unique molecular and clinicopathologic features.
    Zhu C; Ho YJ; Salomao MA; Dapito DH; Bartolome A; Schwabe RF; Lee JS; Lowe SW; Pajvani UB
    J Hepatol; 2021 Mar; 74(3):613-626. PubMed ID: 33038431
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluating the landscape of gene cooperativity with receptor tyrosine kinases in liver tumorigenesis using transposon-mediated mutagenesis.
    Fan Y; Bazai SK; Daian F; Arechederra M; Richelme S; Temiz NA; Yim A; Habermann BH; Dono R; Largaespada DA; Maina F
    J Hepatol; 2019 Mar; 70(3):470-482. PubMed ID: 30529386
    [TBL] [Abstract][Full Text] [Related]  

  • 29. E2F1 inhibits c-Myc-driven apoptosis via PIK3CA/Akt/mTOR and COX-2 in a mouse model of human liver cancer.
    Ladu S; Calvisi DF; Conner EA; Farina M; Factor VM; Thorgeirsson SS
    Gastroenterology; 2008 Oct; 135(4):1322-32. PubMed ID: 18722373
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CSIG promotes hepatocellular carcinoma proliferation by activating c-MYC expression.
    Cheng Q; Yuan F; Lu F; Zhang B; Chen T; Chen X; Cheng Y; Li N; Ma L; Tong T
    Oncotarget; 2015 Mar; 6(7):4733-44. PubMed ID: 25749381
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low expression of c-Myc protein predicts poor outcomes in patients with hepatocellular carcinoma after resection.
    Ji F; Zhang ZH; Zhang Y; Shen SL; Cao QH; Zhang LJ; Li SQ; Peng BG; Liang LJ; Hua YP
    BMC Cancer; 2018 Apr; 18(1):460. PubMed ID: 29690860
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A positive feedback loop involving the LINC00346/β-catenin/MYC axis promotes hepatocellular carcinoma development.
    Zhang N; Chen X
    Cell Oncol (Dordr); 2020 Feb; 43(1):137-153. PubMed ID: 31691159
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Minimal cooperation between mutant Hras and c-myc or TGFα in the regulation of mouse hepatocyte growth or transformation in vivo.
    Stein TJ; Bowden M; Sandgren EP
    Liver Int; 2011 Oct; 31(9):1298-305. PubMed ID: 22093452
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-oncogene PTPN13 inactivation by hepatitis B virus X protein counteracts IGF2BP1 to promote hepatocellular carcinoma progression.
    Yan Y; Huang P; Mao K; He C; Xu Q; Zhang M; Liu H; Zhou Z; Zhou Q; Zhou Q; Ou B; Liu Q; Lin J; Chen R; Wang J; Zhang J; Xiao Z
    Oncogene; 2021 Jan; 40(1):28-45. PubMed ID: 33051595
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oncogene-dependent function of BRG1 in hepatocarcinogenesis.
    Wang P; Song X; Cao D; Cui K; Wang J; Utpatel K; Shang R; Wang H; Che L; Evert M; Zhao K; Calvisi DF; Chen X
    Cell Death Dis; 2020 Feb; 11(2):91. PubMed ID: 32019910
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Critical role of Myc activation in mouse hepatocarcinogenesis induced by the activation of AKT and RAS pathways.
    Xin B; Yamamoto M; Fujii K; Ooshio T; Chen X; Okada Y; Watanabe K; Miyokawa N; Furukawa H; Nishikawa Y
    Oncogene; 2017 Sep; 36(36):5087-5097. PubMed ID: 28481866
    [TBL] [Abstract][Full Text] [Related]  

  • 37. lncRNA SNHG6 functions as a ceRNA to up-regulate c-Myc expression via sponging let-7c-5p in hepatocellular carcinoma.
    Chen S; Xie C; Hu X
    Biochem Biophys Res Commun; 2019 Nov; 519(4):901-908. PubMed ID: 31563323
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regulation of glycosylphosphatidylinositol-anchored proteins and GPI-phospholipase D in a c-Myc transgenic mouse model of hepatocellular carcinoma and human HCC.
    Ritorto MS; Rhode H; Vogel A; Borlak J
    Biol Chem; 2016 Nov; 397(11):1147-1162. PubMed ID: 27232633
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Microtubule associated protein 9 inhibits liver tumorigenesis by suppressing ERCC3.
    Zhang J; Huang JZ; Zhang YQ; Zhang X; Zhao LY; Li CG; Zhou YF; Wei H; Yu J
    EBioMedicine; 2020 Mar; 53():102701. PubMed ID: 32151798
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ADAMTSL5 is an epigenetically activated gene underlying tumorigenesis and drug resistance in hepatocellular carcinoma.
    Arechederra M; Bazai SK; Abdouni A; Sequera C; Mead TJ; Richelme S; Daian F; Audebert S; Dono R; Lozano A; Gregoire D; Hibner U; Allende DS; Apte SS; Maina F
    J Hepatol; 2021 Apr; 74(4):893-906. PubMed ID: 33197513
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.